There is a new COVID-19 booster vaccine in town, just in time for Europe’s fall and winter season.
While they may not have reached market with a vaccine at the height of the pandemic to compete with jabs from the likes of Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), AstraZeneca (LSE: AZN) and Moderna (Nasdaq: MRNA), European pharma heavyweights Sanofi (Euronext: SAN) and GSK (LSE: GSK) have got there with a booster just in time for Europe’s upcoming colder months.
Their vaccine, VidPrevtyn Beta, is the first and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe and was developed with US government funding. The approval was expected following a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze